A Professional Service Provider for the Pharma Industry
WHO compiles a list of antibacterials in clinical development on a regular basis, the last in mid-2024 [1]. The information is up-to-date and detailed: it provides MoA and antibacterial spectrum, coverage of problem pathogens, the development phase, and whether it Continue reading A Critical Review of WHO’s List of Antibacterials in Clinical Development
First and upfront, let’s call this virus WARS*, which stands for Wuhan Associated Respiratory Syndrome. President Xi Jingping called for a war against the new virus, and a war it is. Therefore our acronym makes intuitive sense. The naming of Continue reading Some Thoughts about the New Coronavirus Syndrome and its Transmission
There once was a Scientific American section authored by science historian James Burke called ‘Connections”. In it James Burke, a true renaissance man, showed us how an ‘internet’ of serendipitous encounters, connections between persons, places and events led to advances Continue reading Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB
At the recent FDA workshop on narrow-spectrum antibiotic development[1], the concept of using bacteriological response (BR) as an efficacy endpoint was flat-out rejected. The reason given is the purported lack of correlation between BR and survival/mortality which FDA considers the Continue reading The Weak Correlation Between Antibiotic Action and Mortality
The nomination of Dr. Scott Gottlieb for FDA commissioner, a political appointee, has created the usual bipartisan furor. He is called unqualified, a renegade, not committed enough to FDA orthodoxy, an industry darling by some and a maverick by others. All Continue reading FDA Needs Radical Reform